KESTRA MEDICAL TECHNOLOGIES, LTD.(KMTS)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-04-30.

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KMTS at 28.1/100 on a 32-signal composite quality model, placing it at rank #2,565 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q1 2026), KESTRA MEDICAL TECHNOLOGIES, LTD. reports quarterly revenue of $28.6M, net income of $-38.8M, free cash flow of $-28.4M. Top institutional holders of KMTS by reported 13-F value include BAIN CAPITAL INVESTORS, FMR, PRICE T ROWE ASSOCIATES, based on the most recent SEC filings. KMTS trades on the Nasdaq exchange and files with the SEC under CIK 1877184. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KMTS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for KESTRA MEDICAL TECHNOLOGIES, LTD. directly from SEC EDGAR.